Stock
Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned
US listed securityListed on NASDAQ
US headquarteredHeadquartered in California, United States
Follow
aTyr Pharma Inc
$5.32
LIFE
Mar 19, 2:14:17 PM GMT-4 · USD · NASDAQ · Disclaimer
In the news
Financial performance
| (USD) | Q3 2020 | Year/year change |
|---|---|---|
Revenue | 148.00K | -19.57% |
Net income | -6.60M | -16.90% |
| Diluted EPS | - | - |
| Net profit margin | -4,458.78% | -45.34% |
| Operating income | -6.51M | -18.44% |
| Net change in cash | -3.48M | -222.83% |
| Cash on hand | 18.15M | 4.67% |
| Cost of revenue | 4.62M | 21.51% |
About
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signalling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, CA, and led by CEO Sanjay S. Shukla, M.D., M.S. Wikipedia
Founded
Sep 8, 2005
Headquarters
Website
Employees
42
Key stats
Previous close
The last closing price
$5.26
Day range
The difference between the high and low prices over the past day
$5.16 - $5.56
Year range
The difference between the high and low prices over the past 52 weeks
$2.13 - $8.33
Market cap
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
53.81M USD
Volume
The average number of shares traded each day over the past 30 days
2.42M
P/E ratio
The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks
-
Dividend yield
The ratio of annual dividend to current share price that estimates the dividend return of a stock
-
Primary exchange
Listed exchange for this security
NASDAQ
About
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signalling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, CA, and led by CEO Sanjay S. Shukla, M.D., M.S. Wikipedia
Founded
Sep 8, 2005
Headquarters
Website
Employees
42
